Cormorant Asset Management »

Alumis shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Alumis (ALMS) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Alumis

Tip: Access up to 7 years of quarterly data

All positions including Alumis held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alumis by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $29M 2.1M 13.30

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Alumis

AyurMaya Capital Management Company
Foresite Capital Management V
Samsara BioCapital
venBio Partners
Cormorant Asset Management
Sr One Capital Management
Baker Bros. Advisors
Nextech Invest
BlackRock
Omega Fund Management
Tang Capital Management
TowerView
Morgan Stanley
Geode Capital Management
Iron Triangle Partners

View all funds holding Alumis